Literature DB >> 31379139

Dopamine Delivery via pH-Sensitive Nanoparticles for Tumor Blood Vessel Normalization and an Improved Effect of Cancer Chemotherapeutic Drugs.

Mohammad Taleb1,2, Yanping Ding1, Bin Wang1,2, Na Yang1, Xuexiang Han1,2, Chong Du1, Yingqiu Qi1,3, Yinlong Zhang1, Zeinab Farhadi Sabet1,2, Hamideh Rezvani Alanagh1,2, Ayeesha Mujeeb1, Khosro Khajeh4, Guangjun Nie1,2.   

Abstract

Tumor blood vessels have been reported to be abnormal in both structure and function compared with those in normal tissues, leading to a hostile microenvironment and inadequate antitumor drug delivery. Dopamine, a chemical messenger, is proven to inhibit angiogenesis and improve tumor vessel normalization. Here, a mesoporous silicon nanoparticle (MSN) is constructed that is responsive to the weakly acidic pH of the tumor extracellular matrix for steady delivery and tumor-localized release of dopamine. Then MSNs are functionalized with amine conjugated phenylboronicacid molecules, and dopamine is loaded by reacting with phenylboronic acid. In a weakly acidic environment, MSNs intelligently release dopamine due to the hydrolysis of boronic-ester bond between dopamine and phenylboronic acid, resulting in an evident inhibition of vascular endothelial cell migration and tubule formation. It is shown that loading of dopamine into the functional MSNs significantly prolong the circulatory half-life of this small molecule. After intravenous injection to tumor bearing mice, this nanoformulation induce tumor blood vessel normalization, thereby improving the antitumor chemotherapeutic efficacy of doxorubicin. This study demonstrates that the pH-responsive MSN offers great potential for delivery of dopamine in vivo and the normalization of tumor vessels by dopamine can provide an auxiliary treatment for cancer chemotherapeutic drugs.
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  dopamine; mesoporous silicon nanoparticles; pH responsiveness; tumor vessel normalization

Year:  2019        PMID: 31379139     DOI: 10.1002/adhm.201900283

Source DB:  PubMed          Journal:  Adv Healthc Mater        ISSN: 2192-2640            Impact factor:   9.933


  5 in total

Review 1.  Breaking the niche: multidimensional nanotherapeutics for tumor microenvironment modulation.

Authors:  K Laxmi Swetha; Kavya Sree Maravajjala; Shyh-Dar Li; Manu Smriti Singh; Aniruddha Roy
Journal:  Drug Deliv Transl Res       Date:  2022-06-13       Impact factor: 4.617

2.  Novel mitochondrial targeting charge-reversal polysaccharide hybrid shell/core nanoparticles for prolonged systemic circulation and antitumor drug delivery.

Authors:  Lei Fang; Wei Zhang; Zhen Wang; Xinxin Fan; Ziting Cheng; Xiaoya Hou; Daquan Chen
Journal:  Drug Deliv       Date:  2019-12       Impact factor: 6.419

Review 3.  Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy.

Authors:  Wei Li; Anghui Peng; Huajun Wu; Yingyao Quan; Yong Li; Ligong Lu; Min Cui
Journal:  Front Immunol       Date:  2020-12-21       Impact factor: 7.561

Review 4.  Nanoparticle Surface Functionalization: How to Improve Biocompatibility and Cellular Internalization.

Authors:  Gennaro Sanità; Barbara Carrese; Annalisa Lamberti
Journal:  Front Mol Biosci       Date:  2020-11-26

Review 5.  Recent advances of nanotechnology-based tumor vessel-targeting strategies.

Authors:  Dongjie Zhu; Yang Li; Zhengjia Zhang; Zeyu Xue; Zhenglai Hua; Xinyi Luo; Ting Zhao; Cheng Lu; Yuanyan Liu
Journal:  J Nanobiotechnology       Date:  2021-12-20       Impact factor: 10.435

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.